The specialist nurse role in the treatment of refractory epilepsy

Seizure

Volumn 13, Issue 5, 2004, Pages 303-307

  Hosking, Patricia G ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

AED; ENS; Refractory epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ARTICLE; ATAXIA; BEHAVIOR DISORDER; COARSE FACE; COGNITIVE DEFECT; CONGENITAL MALFORMATION; CONSULTATION; DIPLOPIA; DISEASE EXACERBATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESPONSE; EPILEPSY; FATIGUE; GENERAL PRACTITIONER; GINGIVA DISEASE; HEADACHE; HEALTH CARE PERSONNEL; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; LIVER DISEASE; LIVER METABOLISM; MEDICAL PRACTICE; MEDICAL SPECIALIST; MENSTRUAL IRREGULARITY; MOOD DISORDER; NAUSEA; NEURAL TUBE DEFECT; NURSE; OBESITY; OSTEOMALACIA; OSTEOPENIA; PRIORITY JOURNAL; SALIVATION DISORDER; SEDATION; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TERATOGENICITY; VISUAL FIELD DEFECT; VITAMIN K DEFICIENCY;

EID: 2942702122     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2003.08.001     Document Type: Article

References (33)

1. Elwes R, Johnson A, Shorvon S, Reynolds E. The prognosis for seizure control in newly diagnosed epilepsy. New England Journal of Medicine 1984;311:944-7.
2. Chadwick DW. An overview of the efficacy and tolerability of new antiepileptic drugs. Epilepsia 1997;38(Suppl 1):S59-62.
3. Baker GA, Jacoby A, Buck D, Stalgis C, Monnet D. The quality of life of people with epilepsy: a European study. Epilepsia 1997;38:353-62.
4. Hanna NJ, Black M, Sander JW, et al. National Sentinel Clinical Audit of Epilepsy-retated Death: Epilepsy-Death in the Shadows. The Stationery Office, 2002.
5. Services for People with Epilepsy. Clinical Standards Advisory Group, 1999.
6. Scheyer RD, Cramer JA. Pharmacokinetics of antiepileptic drugs. Seminars in Neurology 1990;10(4):414-21.
7. Gram L. Pharmacokinetics of new antiepileptic drugs. Epilepsia 1996;37(Suppl 6):S12-6.
8. Gisclon LG, Curtin CR, Kramer LD. The steady-state pharmacokinetics of phenytoin and topiramate in epileptic patients on monotherapy and during combination therapy. Epilepsia 1994;35(Suppl 8):54.
9. Fattore C, Cipolla G, Gatti G, et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 1999;40(6):783-7.
10. Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999;40(7):985-91.
11. Holland KD. Efficacy, pharmacology, and adverse effects of antiepileptic drugs. Neurologic Clinics 2001;19(2):313-45.
12. Mattson RH. Efficacy and adverse effects of established and new antiepileptic drugs. Epilepsia 1995;36(Suppl):S13-26.
13. Wallace S. A comparative review of the adverse effects of AEDs in children with epilepsy. Drug Safety 1996;15(6):378-93.
14. Isojarvi JIT, Laatikainen TJ, Knip M, Parkarinen AJ, Juntunen KT, Myllya VV. Obesity and endocrine disorders in women taking valproate for epilepsy. Annals of Neurology 1996;39:579-84.
15. Pack AM, Morrell MJ. Treatment of women with epilepsy. Seminars in Neurology 2002;22(3):289-98.
16. Clarkson PM, James AG. Parenteral vitamin K1: the effective prophylaxis against haemorrhagic disease for all newborn infants. The New Zealand Medical Journal 1990;103(885):95-6.
17. Kelly TE, Edwards P, Rein M, Miller JQ, Deifuss FE. Teratogenicity of anticonvulsant drugs. 11: a prospective trial. American Journal of Medical Genetics 1984;19:435-43.
18. Kaneko S, Otani K, Fukishima J, et al. Teratogenicity of antiepiteptic drugs: analysis of possible risk factors. Epilepsia 1988;29:459-67.
19. Brodie MJ, Overstall PW, Giorgi L. Multi-centre double blind randomised comparative study between LTG and CBZ in elderly patients with newly diagnosed epilepsy. Epilepsy Research 1999;37():81-7.
20. Cloyd JC, Lackner TE. AEDs in the elderly: pharmacoepidemiology and pharmacokinetics. Archives of Family Medicine 1994;7:589-98.
21. Walker J, Wynne H. Review: the frequency and severity of adverse drug reactions in elderly people. Age Aging 1994;23:255-9.
22. Schmitz B, Schmidt T, Jokiel B, Pfeiffer S, Tiel-Wilck K, Ruther K. Visual field constriction in epilepsy patients treated with vigabatrin and other antiepileptic drugs: a prospective study. Journal of Neurology 2002;249(4):469-75.
23. Glauser TA, Clark PO. A pilot study of Topiramate and the treatment of infantile spasms. Epilepsia 1998;39(12):1324-8.
24. Sachdeo SK, Sachdeo RC, Kugler SL. An open labet evaluation of topiramate in Lennox-Gasteau syndrome. Epilepsia 1996;37(Suppl 5):112.
25. Buchannan N. The efficacy of lamotrogine and seizure control in 34 children, adolescents and young adults with intellectual and physical disability. Seizure 1995;4:233-6.
26. Timmins PL, Richens A. Lamotrogine as add-on drug in the management of Lennox-Gasteau syndrome. Eur Neurol 1992;32:305-7.
27. Shields WD, Saslow E. Myoclonic, atonic and absence seizures following initiation of carbamazepine therapy. Neurology 1983;33:1487-9.
28. Berkovic SJ. Aggravation of generalised epilepsy. Epilepsia 1998;39(Suppl 3):S11-4.
29. Levy LL, Fenichel AM. Diphenylhydantoin activated seizures. Neurology 1965;15:716-22.
30. Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998;39(5):508-12.
31. Genton P, Dravet C, Bureau M, Formosa F, Mesdjian E. Aggravation of severe myoclonic epilepsy by lamotrogine. Epilepsia 1997;38(Suppl 3):32.
32. Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998;39(1):5-17.
33. Hosking PG, Duncan JS, Sander JW. The epilepsy nurse specialist at a Tertiary Care Hospital-improving the interface between primary and tertiary care. Seizure 2002;11:494-9.